REG - SkinBioTherapeutics - Appointment of Interim CEO

SkinbiotherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB8127Ua&default-theme=true

RNS Number : 8127U  SkinBioTherapeutics PLC  02 March 2026

 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Appointment of Interim CEO

 

2 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science
business focused on skin health, has appointed Rachel Parsonage as Interim CEO
for a period of six months, during which time she will also serve as a member
of the Board. Rachel will commence her duties with immediate effect and she
will be introduced to the rest of the team this morning. Her appointment to
the Board is subject to the completion of normal regulatory due diligence
being carried out by the Company's Nominated Adviser.

Rachel is a seasoned senior executive with over 25 years' experience leading
consumer beauty and wellness businesses through growth and change. She has
held CEO and transformational level leadership roles across owned and licensed
brand portfolios in both domestic and international markets. She has been
involved in financial and business model management, operations and inventory
management, and the strengthening of corporate governance. Rachel has also
worked closely with boards, founders, lenders and partners to navigate periods
of transition.

Currently, Rachel runs her own advisory consultancy, Alera Advisory. Before
then, she was at KMI Brands for over 16 years, rising from Managing Director
to Chief Executive, where she scaled and stabilised a portfolio of owned and
licensed beauty brands. Before then, Rachel was Managing Director at This
Works, a premium British aromatherapy and skincare brand with UK and US focus,
and previously, she was owner of Vita Management, an independent consultancy.
Prior to this, she was General Manager at Pacific Direct, a global hotel
manufacturing amenity company providing brand development for hotels working
with luxury brands, Elemis, Penhaligons and White Company. Rachel is an
alumnus of the Business Growth Programme (BGP), part of Cranfield's Executive
Development Programme.

Martin Hunt, Executive Chairman of SkinBioTherapeutics, said:

"In the past few weeks, our aim has been to take decisive action to stabilise
the business, including the search for a new interim CEO, while we undertake a
thorough investigation to resolve the current issues. We are therefore
delighted to welcome Rachel to the team as interim CEO. Her background matches
our immediate requirements exactly; she has over 32 years in total in the
consumer and wellness sector, with a clear track record of stabilising brands
and companies, managing stakeholders including partners, and driving sales and
IP commercialisation.

"This appointment is one part of our plan to resolve the current issues as
quickly as possible. With respect to the forensic investigation, we are
balancing the thoroughness of an investigation within a clear cost-benefit
framework, to remove any uncertainty around the business' future. We want
SkinBioTherapeutics to get back on track, move forward and focus on
accelerating its growth again."

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  ir@skinbiotix.com
 Martin Hunt, Executive Chairman

Emily Bertram, CFO
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

Philip Davies

James Todd

Patrick Weaver
 Vigo Consulting                                          +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris                        SkinBio@vigoconsulting.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.SkinBioTherapeutics.com
(http://www.skinbiotherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKVLFLQLLEBBV



            Copyright 2019 Regulatory News Service, all rights reserved